Add-on ralinepag delays first clinical worsening event in PAH

ORLANDO — Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening event in patients with pulmonary arterial hypertension, according to phase 3 ADVANCE OUTCOMES trial results.These findings were presented at the American Thoracic Society International Conference.